Nathan Pennell is an Oncology physician affiliated with Cleveland Clinic. OpenAlex indexes 424 publications with 68,849 citations (h-index 85); ClinicalTrials.gov lists 9 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 1% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9500 Euclid Ave
Cleveland, OH 441950001
Telephone
216-444-2200Registry record last updated 21 Oct 2011.
Clinical trials
- Liquid Biopsy to Reduce Time to Treatment for Advanced Nonsquamous NSCLC Diagnosed at Outside Sites
Sponsor: Case Comprehensive Cancer Center
- Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC
Sponsor: Nathan Pennell, MD, PhD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20251 payment
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
- Takeda Pharmaceuticals U.S.A., Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
24.9%Serotonin-3 Receptor Antagonist12.3%Ondansetron Hcl100%Part D≥21 patientsPotassium supplement7.4%Potassium Chloride100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
20.7%Kinase inhibitor20.7%Tagrisso66%Alecensa34%Part D<11 patientsBlood & clotting
15.8%Factor Xa inhibitor15.8%Eliquis51%Xarelto49%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Samir Kapadia, MD
Cleveland Clinic
Mina Chung, MD
Cleveland Clinic
Serpil Erzurum, MD
Cleveland Clinic
Arthur McCullough, MD
Cleveland Clinic
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”